Treat-to-target in systemic lupus erythematosus: Cytokine Transduction Pathways in SLE

Editors

Impact

The panel shows the expression of six types of I-IFN stimulated genes, indicated in the X axis. Red bars indicate expression levels in the patient; black bars represent the average of 20 healthy donors. The interferon score (FI) is indicated in the legend.

Case Report

06 December 2023

Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with Jak-inhibitors: a case report

Martina Rossano

, 7 more and

Giovanni Filocamo

2,797 views

5 citations

Spearman’s rank correlations between levels of different cytokines and SLEDAI-2K scores. Statistically significant correlations are denoted by asterisks. BAFF, B cell activating factor belonging to the tumour necrosis factor ligand family; CCL13, C-C motif chemokine ligand 13; CCL17, C-C motif chemokine ligand 17; CCL18; C-C motif chemokine ligand 18; CCL2; C-C motif chemokine ligand 2; CCL20; C-C motif chemokine ligand 20; CCL3; C-C motif chemokine ligand 3; CCL4; C-C motif chemokine ligand 4; CCL5; C-C motif chemokine ligand 5; CCL7; C-C motif chemokine ligand 7; CCL8; C-C motif chemokine ligand 8; CRP, C-reactive protein, CXCL1, C-X-C motif ligand 1; CXCL10, C-X-C motif ligand 10; CXCL11, C-X-C motif ligand 11; CXCL13, C-X-C motif ligand 13, CXCL16, C-X-C motif ligand 16; CXCL5, C-X-C motif ligand 5; CXCL9, C-X-C motif ligand 9; DcR1, decoy receptor 1; DcR3, decoy receptor 3; EGF, epidermal growth factor; FasL; Fas ligand; FGF2, fibroblast growth factor 2; FGF21, fibroblast growth factor 21; G-CSF, granulocyte colony-stimulating factor; GDF15, growth differentiation factor 15; GH, growth hormone; HGF, hepatocyte growth factor; ICAM-1, intercellular adhesion molecule 1; IFN-γ, interferon γ; IFNGR1, interferon γ receptor 1; IL-10, interleukin 10; IL-12, interleukin 12; IL-13, interleukin 13; IL-17A, interleukin 17A; IL-17F, interleukin 17F; IL-18BP, interleukin 18 binding protein; IL-1R1, interleukin 1 receptor type 1; IL-1R2, interleukin 1 receptor type 2; IL-1RA, interleukin 1 receptor antagonist; IL-1α, interleukin 1α; IL-1β, interleukin 1β; IL-2, interleukin 2; IL-23, interleukin 23; IL-27, interleukin 27; IL-28A, interleukin 28A; IL-2Rα, interleukin 2 receptor α; IL-31, interleukin 31; IL-33, interleukin 33; IL-5, interleukin 5; IL-6, interleukin 6; IL-6Rα, interleukin 6 receptor α; IL-8, interleukin 8; M-CSF, macrophage colony-stimulating factor; MDC, macrophage-derived chemokine; MIF, macrophage migration inhibitory factor; MMP-1, matrix metalloproteinase 1; MMP-13, matrix metalloproteinase 13; MMP-2, matrix metalloproteinase 12; MMP-3, matrix metalloproteinase 3; MMP-7, matrix metalloproteinase 7; MMP-8, matrix metalloproteinase 8; MMP-9, matrix metalloproteinase 9; MPO, myeloperoxidase; PF4, platelet factor 4; PTX3, pentraxin 3; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; TACI, transmembrane activator and calcium modulator and cyclophilin ligand interactor; TGF-β, transforming growth factor β; TNF-α, tumour necrosis factor α; TNFR1, tumour necrosis factor receptor 1; TNFR2, tumour necrosis factor receptor 2; VCAM-1, vascular cell adhesion protein 1; VEGF, vascular endothelial growth factor; VEGF-C, vascular endothelial growth factor C; VEGFR3, vascular endothelial growth factor receptor 3.

Original Research

30 November 2023

Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus

Julius Lindblom

, 69 more and

Héctor Navarro-Linares.

3,283 views

4 citations

Original Research

14 June 2024

Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study

Cuiling Fan

, 5 more and

Juan Li

2,501 views

2 citations

Review

28 June 2024

The dualistic role of Lyn tyrosine kinase in immune cell signaling: implications for systemic lupus erythematosus

Elan L’Estrange-Stranieri

, 2 more and

Margaret L. Hibbs

2,465 views

2 citations

Review

12 September 2023

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

Yi-Giien Tsai

, 4 more and

Kuender D. Yang

Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.

7,273 views

11 citations